Earnings summaries and quarterly performance for Wave Life Sciences.
Executive leadership at Wave Life Sciences.
Board of directors at Wave Life Sciences.
Research analysts who have asked questions during Wave Life Sciences earnings calls.
Catherine Novack
JonesTrading Institutional Services LLC
6 questions for WVE
Also covers: ALDX, CAPR, CRNX +3 more
JL
Joon Lee
Truist Securities
6 questions for WVE
Also covers: ADVM, ALKS, AXSM +15 more
SS
Salim Syed
Mizuho Securities
6 questions for WVE
Also covers: AUTL, BBIO, CYTK +6 more
MW
Madison Wynne El-Saadi
B. Riley Securities
4 questions for WVE
Also covers: AGEN, CAPR, ETON +1 more
Cheng Li
Oppenheimer & Co. Inc.
3 questions for WVE
Also covers: EDIT, EXEL, INO +3 more
JS
Joseph Schwartz
Oppenheimer
3 questions for WVE
Also covers: ASND, AUPH, BMRN +14 more
Steve Seedhouse
Cantor Fitzgerald
3 questions for WVE
Also covers: BCRX, BOLD, HROW +1 more
AR
Alex Ranahan
Bank of America Securities
2 questions for WVE
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for WVE
Also covers: ACRS, CRVS, CTMX +12 more
LY
Lillian Yuen-Ho
RBC Capital Markets
2 questions for WVE
LW
Lisa Walter
RBC Capital Markets
2 questions for WVE
Also covers: APLS, EYPT, OCUL +3 more
ME
Madison El-Saadi
B. Riley
2 questions for WVE
Also covers: ARWR, VNDA
MK
Michael King
Rodman & Renshaw
2 questions for WVE
RS
Roger Song
Jefferies
2 questions for WVE
Also covers: AADI, AKBA, ALT +14 more
RF
Ron Feiner
Leerink Partners
2 questions for WVE
Also covers: KYMR
Ananda Ghosh
H.C. Wainwright & Co.
1 question for WVE
Also covers: ABOS, ALEC, AMLX +1 more
AF
Andrew Fein
H.C. Wainwright & Co.
1 question for WVE
Also covers: VTGN
A
Angela
Canaccord Genuity
1 question for WVE
Also covers: BEAM
Anthony
Raymond James
1 question for WVE
Also covers: AB, APAM, APLS +2 more
BB
Benjamin Burnett
Stifel, Nicolaus & Company, Incorporated
1 question for WVE
Also covers: AXSM, IOVA, PGEN +2 more
Cha Cha Yang
Jefferies
1 question for WVE
Also covers: NKTR, TGTX
C
Craig
Wells Fargo
1 question for WVE
Eric Joseph
JPMorgan Chase & Co.
1 question for WVE
Also covers: BEAM, BLUE, ENTA +9 more
J
Jenny
Leerink Partners
1 question for WVE
Jenny Leigh Gonzalez-Armenta
Leerink Partners
1 question for WVE
Also covers: QURE
JS
Joe Schwartz
Leerink Partners
1 question for WVE
Also covers: BMRN, CRNX, INSM +3 more
LI
Luca Issi
RBC Capital Markets
1 question for WVE
Also covers: ADVM, ALLO, ALNY +13 more
Martin Auster
Raymond James
1 question for WVE
Also covers: PHAT
NE
Nicholas Econom
Raymond James
1 question for WVE
Also covers: APLS, EDIT
Ryan Deschner
Raymond James Financial
1 question for WVE
Also covers: APLS, ARDX, ARSP +7 more
Samantha Semenkow
Citigroup Inc.
1 question for WVE
Also covers: AGIO, ALLO, ARGX +10 more
SS
Steven Seedhouse
Raymond James
1 question for WVE
Also covers: APLS, BCRX, EDIT +2 more
TF
Tiago Fauth
Wells Fargo
1 question for WVE
Also covers: LQDA, PTCT, VRNA
WI
Whitney Ijem
Canaccord Genuity Inc.
1 question for WVE
Also covers: ARCT, BOLD, GUTS +5 more
YJ
Yun Jung
Wedbush Securities
1 question for WVE
Yun Zhong
Wedbush Securities
1 question for WVE
Also covers: ASND, MNKD, MRKR +2 more
Recent press releases and 8-K filings for WVE.
Wave Life Sciences Provides Pipeline Update and Anticipates New Clinical Data
WVE
New Projects/Investments
Guidance Update
- Wave Life Sciences reported Q4 results and anticipates releasing additional clinical data this quarter for its key programs.
- For its obesity program, WVE-007, new clinical data is expected this quarter, including six-month data from the 240 mg cohort and three-month data from the 400 mg cohort. Previous 240 mg data showed a 10% reduction in visceral fat and sustained lean mass. The company is also accelerating the Phase 2a study for WVE-007 to include higher BMI patients and those with comorbidities, with initiation planned for the first half of the year.
- For WVE-006, its RNA editing program for alpha-1 antitrypsin deficiency, additional 400 mg multi-dose data is expected this quarter. The company is exploring pathways for accelerated approval and plans regulatory engagement in mid-2026.
1 day ago
Wave Life Sciences Discusses Q4 Results and Upcoming Clinical Data for WVE-007 and WVE-006
WVE
New Projects/Investments
- Wave Life Sciences reported 4Q results and is anticipating significant clinical data this quarter (Q1 2026) for its lead programs.
- For WVE-007, an obesity treatment, upcoming data includes 240 mg six-month data and 400 mg three-month data, building on initial results showing nearly 10% visceral fat reduction and preserved lean mass. The company is accelerating a Phase 2a study for higher BMI patients and aims for a differentiated label focusing on body composition.
- For WVE-006, an RNA editing program for alpha-1 antitrypsin deficiency, 400 mg multi-dose data is expected this quarter, with the company pursuing accelerated approval based on its ability to correct protein levels.
- The company is also advancing early discovery work on bifunctional modalities and expanded tissue targeting, including the potential to incorporate Inhibin E into these new approaches.
1 day ago
Wave Life Sciences Discusses Q4 Results and Pipeline Updates
WVE
New Projects/Investments
Product Launch
- Wave Life Sciences reported Q4 results and provided updates on its clinical pipeline, including upcoming data readouts for its lead programs.
- For WVE-007 (obesity), the company anticipates releasing 6-month data from the 240 mg cohort and 3-month data from the 400 mg cohort in Q1 2026, following initial 3-month data that showed a ~10% reduction in visceral fat and sustained lean mass. A Phase 2a study for WVE-007 in higher BMI patients is scheduled to begin in H1 2026.
- For WVE-006 (alpha-1 antitrypsin deficiency), data from the 400 mg multi-dose cohort is expected in Q1 2026, building on prior data where patients achieved a 20 micromolar response. The company is also engaged in regulatory discussions for potential accelerated approval.
- Wave is also advancing early discovery work on bifunctional modalities that combine knockdown and editing in a single molecule, with potential for dual targeting of cell types like adipocytes and liver cells.
1 day ago
Wave Life Sciences Reports Q4 and Full Year 2025 Financial Results and Provides Pipeline Updates
WVE
Earnings
Guidance Update
New Projects/Investments
- Wave Life Sciences reported a net loss of $204.4 million for the full year 2025, with revenue decreasing to $42.7 million from $108.3 million in 2024, primarily due to the termination of the Takeda collaboration.
- The company concluded 2025 with $602.1 million in cash and cash equivalents, projecting a cash runway into the third quarter of 2028.
- Interim Phase 1 data for WVE-007 in obesity demonstrated a 9.2% reduction in visceral fat and muscle preservation after a single dose, with a Phase IIa multi-dose trial set to begin in the first half of 2026 and further data expected later this quarter.
- For WVE-006 in AATD, regulatory feedback on a potential accelerated approval pathway is anticipated mid-2026, and additional clinical data from the RestorAATion-2 trial is expected this quarter and in 2026.
- The company is also progressing WVE-008 for PNPLA3 I148M liver disease with a CTA submission planned for 2026, and an NDA submission for WVE-N531 in DMD is on track for accelerated approval in 2026.
2 days ago
Wave Life Sciences Reports Q4 and Full Year 2025 Results, Highlights Clinical Progress and Strong Cash Position
WVE
Earnings
Guidance Update
New Projects/Investments
- Wave Life Sciences reported Q4 2025 revenue of $17.2 million and a full-year 2025 net loss of $204.4 million, with the revenue decrease primarily attributed to the termination of the Takeda collaboration.
- The company ended 2025 with $602.1 million in cash and cash equivalents, which is expected to fund operations into Q3 2028.
- Positive interim data for WVE-007 (obesity) from the INLIGHT study showed a 4% reduction in total fat and 9.2% reduction in visceral fat with muscle preservation at 3 months, and the Phase IIa multi-dose portion is expected to initiate in the first half of 2026.
- Wave anticipates regulatory feedback for a potential accelerated approval pathway for WVE-006 (AATD) in mid-2026, and plans NDA submission for WVE-N531 (DMD) and CTA submission for WVE-008 (PNPLA3 I148M liver disease) in 2026.
2 days ago
Wave Life Sciences Reports Q4 and Full Year 2025 Financial Results and Provides Pipeline Updates
WVE
Earnings
Guidance Update
New Projects/Investments
- Wave Life Sciences reported Q4 2025 revenue of $17.2 million and a full-year 2025 net loss of $204.4 million, ending the year with $602.1 million in cash and cash equivalents projected to fund operations into Q3 2028.
- The company shared positive interim data for its obesity candidate, WVE-007, from the INLIGHT study, demonstrating fat loss similar to semaglutide without muscle loss at the lowest therapeutic dose, with further data expected this quarter and Phase IIa initiation in H1 2026.
- For WVE-006 in AATD, regulatory feedback on a potential accelerated approval pathway is anticipated in mid-2026, and data from the 400 mg multi-dose cohort of the RestorAATion-2 trial is expected this quarter.
- The collaboration with GSK continues to advance, with a fourth program selected for development, triggering a milestone payment in Q1 2026, and potential future milestones totaling up to $2.8 billion.
2 days ago
Wave Life Sciences Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
WVE
Earnings
Guidance Update
New Projects/Investments
- Wave Life Sciences reported a net loss of $53.2 million for the fourth quarter of 2025 and $204.4 million for the full year 2025. Revenue for Q4 2025 was $17.2 million, and for the full year 2025, it was $42.7 million.
- The company is well capitalized with $602.1 million in cash and cash equivalents as of December 31, 2025, and expects this to fund operations into Q3 2028.
- Key clinical milestones include an INLIGHT clinical data update for WVE-007 (obesity) in Q1 2026 and the initiation of the Phase 2a multidose portion of WVE-007 in 1H 2026.
- Regulatory advancements include anticipated feedback on a potential accelerated approval pathway for WVE-006 (AATD) by mid-2026, and CTA submission for WVE-008 (PNPLA3 liver disease) and NDA submission for WVE-N531 (DMD) are both on track for 2026.
2 days ago
Wave Life Sciences Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
WVE
Earnings
Guidance Update
New Projects/Investments
- Wave Life Sciences reported a net loss of $204.4 million for the full year 2025, compared to a net loss of $97.0 million in 2024, with revenue of $42.7 million for 2025.
- The company ended 2025 with $602.1 million in cash and cash equivalents, providing a cash runway into 3Q 2028.
- Significant pipeline advancements are expected in 2026, including an INLIGHT clinical data update for WVE-007 (obesity) in 1Q 2026, anticipated regulatory feedback for an accelerated approval pathway for WVE-006 (AATD) by mid-2026, and a New Drug Application (NDA) filing for WVE-N531 (DMD).
- Preparations are also underway for a Clinical Trial Application (CTA) filing for WVE-008 (PNPLA3 I148M liver disease) in 2026.
2 days ago
Wave Life Sciences Regains Full Rights to WVE-006, Plans Accelerated Regulatory Pathway, and Updates on GSK Collaboration
WVE
Product Launch
New Projects/Investments
Guidance Update
- Wave Life Sciences has regained full rights to WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD) from GSK.
- The company plans to engage the FDA on a potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated by mid-2026.
- Data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial are on track for the first quarter of 2026, and data from the 600 mg single and multidose cohorts are expected in 2026.
- The research collaboration with GSK is ongoing, with a fourth program selected to advance in January 2026, potentially making Wave eligible for up to $2.8 billion in milestones.
- Wave continues to expect its current cash and cash equivalents to fund operations into the third quarter of 2028.
Feb 2, 2026, 12:41 PM
Wave Life Sciences Regains Full Rights to WVE-006 and Updates on Pipeline and Cash Runway
WVE
New Projects/Investments
Guidance Update
Product Launch
- Wave Life Sciences has regained full rights to WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD) from GSK and plans to engage the FDA on a potential accelerated approval pathway, with regulatory feedback anticipated mid-2026.
- Clinical trial data for WVE-006's 400 mg multidose cohort are on track for the first quarter of 2026, with 600 mg cohort data expected later in 2026.
- The research collaboration with GSK is expanding, with a fourth program selected in January 2026, potentially yielding up to $2.8 billion in milestones and royalties for Wave.
- Wave anticipates its cash runway will extend into the third quarter of 2028.
Feb 2, 2026, 12:30 PM
Quarterly earnings call transcripts for Wave Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more